CO4970816A1 - Combinaciones de estatina-eter carboxialquilico - Google Patents

Combinaciones de estatina-eter carboxialquilico

Info

Publication number
CO4970816A1
CO4970816A1 CO98073828A CO98073828A CO4970816A1 CO 4970816 A1 CO4970816 A1 CO 4970816A1 CO 98073828 A CO98073828 A CO 98073828A CO 98073828 A CO98073828 A CO 98073828A CO 4970816 A1 CO4970816 A1 CO 4970816A1
Authority
CO
Colombia
Prior art keywords
statin
combinations
pharmaceutically acceptable
carboxyalkyl ether
ether
Prior art date
Application number
CO98073828A
Other languages
English (en)
Spanish (es)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO4970816A1 publication Critical patent/CO4970816A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CO98073828A 1997-12-12 1998-12-11 Combinaciones de estatina-eter carboxialquilico CO4970816A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6937597P 1997-12-12 1997-12-12

Publications (1)

Publication Number Publication Date
CO4970816A1 true CO4970816A1 (es) 2000-11-07

Family

ID=22088573

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98073828A CO4970816A1 (es) 1997-12-12 1998-12-11 Combinaciones de estatina-eter carboxialquilico

Country Status (30)

Country Link
EP (1) EP1045691B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002508320A (cg-RX-API-DMAC7.html)
KR (1) KR20010033003A (cg-RX-API-DMAC7.html)
AR (1) AR017851A1 (cg-RX-API-DMAC7.html)
AT (1) ATE285762T1 (cg-RX-API-DMAC7.html)
AU (1) AU754089B2 (cg-RX-API-DMAC7.html)
BR (1) BR9813542A (cg-RX-API-DMAC7.html)
CA (1) CA2304612A1 (cg-RX-API-DMAC7.html)
CO (1) CO4970816A1 (cg-RX-API-DMAC7.html)
CR (1) CR5926A (cg-RX-API-DMAC7.html)
CU (1) CU20000140A7 (cg-RX-API-DMAC7.html)
DE (1) DE69828442T2 (cg-RX-API-DMAC7.html)
DK (1) DK1045691T3 (cg-RX-API-DMAC7.html)
ES (1) ES2230733T3 (cg-RX-API-DMAC7.html)
GT (1) GT199800196A (cg-RX-API-DMAC7.html)
HN (1) HN1998000185A (cg-RX-API-DMAC7.html)
HU (1) HUP0004547A3 (cg-RX-API-DMAC7.html)
IL (1) IL135349A0 (cg-RX-API-DMAC7.html)
IS (1) IS2150B (cg-RX-API-DMAC7.html)
MY (1) MY118381A (cg-RX-API-DMAC7.html)
NO (1) NO20002966L (cg-RX-API-DMAC7.html)
NZ (1) NZ503982A (cg-RX-API-DMAC7.html)
PA (1) PA8464601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20000017A1 (cg-RX-API-DMAC7.html)
PL (1) PL341066A1 (cg-RX-API-DMAC7.html)
PT (1) PT1045691E (cg-RX-API-DMAC7.html)
SV (1) SV1998000146A (cg-RX-API-DMAC7.html)
UY (1) UY25299A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999030704A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA9811348B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
CA2299397A1 (en) * 1997-12-12 1999-06-24 Warner-Lambert Company Antihyperlipidemic statin-lp(a) inhibitor combinations
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
CZ20011035A3 (cs) * 1998-09-30 2001-10-17 Warner-Lambert Company Léčivo pro prevenci nebo oddálení revaskularizace pomocí katetru u pacientů postiľených chorobou koronární artérie
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
IN191580B (cg-RX-API-DMAC7.html) * 1999-12-17 2003-12-06 Ranbaxy Lab Ltd
NZ519550A (en) 2000-01-25 2003-11-28 Warner Lambert Co Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
AU2001256278A1 (en) * 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
CZ20023459A3 (cs) * 2000-04-26 2003-05-14 Warner-Lambert Company Antihypertensní činidla a jejich použití
US6689807B1 (en) * 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
CA2450820C (en) * 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
JP6295205B2 (ja) * 2012-01-06 2018-03-14 ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. 心血管疾患のリスクを低減する方法
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases

Also Published As

Publication number Publication date
NO20002966D0 (no) 2000-06-09
IL135349A0 (en) 2001-05-20
JP2002508320A (ja) 2002-03-19
EP1045691B1 (en) 2004-12-29
IS5445A (is) 2000-04-14
ES2230733T3 (es) 2005-05-01
GT199800196A (es) 2000-06-03
SV1998000146A (es) 1999-09-30
WO1999030704A1 (en) 1999-06-24
EP1045691A1 (en) 2000-10-25
HN1998000185A (es) 1999-06-02
CR5926A (es) 2000-03-06
DE69828442D1 (de) 2005-02-03
CA2304612A1 (en) 1999-06-24
KR20010033003A (ko) 2001-04-25
NO20002966L (no) 2000-06-09
BR9813542A (pt) 2000-10-10
AU1591599A (en) 1999-07-05
HUP0004547A3 (en) 2001-12-28
IS2150B (is) 2006-10-13
PA8464601A1 (es) 2001-12-14
MY118381A (en) 2004-10-30
NZ503982A (en) 2002-03-28
PL341066A1 (en) 2001-03-26
AR017851A1 (es) 2001-10-24
ATE285762T1 (de) 2005-01-15
DK1045691T3 (da) 2005-03-14
ZA9811348B (en) 1999-06-14
PT1045691E (pt) 2005-03-31
CU20000140A7 (es) 2005-10-19
HUP0004547A2 (hu) 2001-05-28
AU754089B2 (en) 2002-11-07
PE20000017A1 (es) 2000-01-20
DE69828442T2 (de) 2005-06-02
UY25299A1 (es) 2001-08-27

Similar Documents

Publication Publication Date Title
IT1255895B (it) Composizioni farmaceutiche contenenti una calcitonina
CO4950529A1 (es) Dihidropirimidinas y productos que las contienen
AP9901534A0 (en) Pharmaceutical formulations.
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
IL109503A0 (en) Hiv protease inhibitors and pharmaceutical compositions containing them
PT981375E (pt) Composicoes farmaceuticas contendo proteinas do plasma
FI965036A7 (fi) Interleukiini-beta:aa muuttavan entsyymin inhibiittoreita sekä niitä sisältävät farmaseuttiset koostumukset
IL99163A0 (en) Inhibitors for serine proteases,their preparation and pharmaceutical compositions containing them
FI955042L (fi) Syklosporiinia sisältävä jauhemainen koostumus
IL135377A0 (en) Pharmaceutical compositions comprising mtp inhibitors
DZ2086A1 (fr) Benzylaminopipéridines substituées et compositionspharmaceutiques les contenant.
HUP0102250A3 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
FI960849A7 (fi) Metallikomplekseja sisältäviä farmaseuttisia koostumuksia
ATE231393T1 (de) Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend
MA22989A1 (fr) Compositions pour le nettoyage corporel contenant un alcool ethoxyglyceryl sulfonate de sodium.
FI954580L (fi) HIV-proteaasin estäjiä farmaseuttisissa yhdistelmissä käytettäväksi AIDSin hoitoon
AU1943899A (en) Methods for delivering pharmaceutical agents to mucosal surfaces
FR2774687B1 (fr) Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FI971566L (fi) Kompakti lääkeannostelija sisäänhengitettävien lääkepartikkelien generoimiseksi
IL141914A0 (en) Dosage form comprising liquid formulation
MA23153A1 (fr) Composition detergente liquide contenant un insecticide
ZA965969B (en) Salts derived from amidine and cyclooxygenase inhibitor process for the preparation thereof their application as medicinal drugs and pharmaceutical compositions in which they are contained
EP0638637A3 (en) Acidic liquid detergent for bathrooms.
FI954986L (fi) Uudet, suun kautta annettavat, syklosporiinia sisältävät farmaseuttiset valmisteet
PT862575E (pt) Novos derivados de geranilgeranilo processo para a sua preparacao e composicoes farmaceuticas relacionadas